AI assistant
Sending…
bioAffinity Technologies, Inc. — Director's Dealing 2024
Apr 24, 2024
35439_dirs_2024-04-24_e23813bb-092d-4f81-9b9d-65b763443082.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-04-04
Reporting Person: Zannes Timothy P (Secretary, EVP, Gen. Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-04 | Common Stock | M | 64848 | $1.16 | Acquired | 75155 | Direct |
| 2024-04-04 | Common Stock | F | 29031 | $2.58 | Disposed | 46124 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-04 | Stock Option (right to buy) | $1.16 | M | 64848 | Disposed | 2024-04-28 | Common Stock (64848) | Direct |
Footnotes
F1: Represents shares withheld to cover the exercise price of the options exercised.
F2: This option vested in 7 equal monthly installments beginning on April 28, 2014.
More from bioAffinity Technologies, Inc.
Regulatory Filings
2026
Jun 2
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 12
Earnings Release
2026
May 8
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 14
Regulatory Filings
2026
Apr 7
Investor Presentation
2026
Mar 26